|
gptkbp:instanceOf
|
gptkb:drug
glucagon-like peptide-1 receptor agonist
|
|
gptkbp:administeredBy
|
subcutaneous injection
|
|
gptkbp:approvedBy
|
gptkb:European_Medicines_Agency
gptkb:U.S._Food_and_Drug_Administration
2016 (US)
2013 (EU)
|
|
gptkbp:ATCCode
|
A10BJ03
|
|
gptkbp:brand
|
gptkb:Adlyxin
|
|
gptkbp:CASNumber
|
320367-13-3
|
|
gptkbp:contraindication
|
history of hypersensitivity to lixisenatide
|
|
gptkbp:developedBy
|
gptkb:Sanofi
|
|
gptkbp:eliminationHalfLife
|
2-4 hours
|
|
gptkbp:hasMolecularFormula
|
C215H347N61O65S
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
lixisenatide
|
|
gptkbp:KEGGID
|
D09716
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
slows gastric emptying
increases insulin secretion
suppresses glucagon secretion
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:proteinBinding
|
55%
|
|
gptkbp:PubChem_CID
|
25154894
CHEMBL2108706
DB08875
|
|
gptkbp:routeOfAdministration
|
subcutaneous
|
|
gptkbp:sideEffect
|
gptkb:hypoglycemia
nausea
vomiting
diarrhea
|
|
gptkbp:UNII
|
0C2J4N2Z4B
|
|
gptkbp:usedFor
|
gptkb:type_2_diabetes_mellitus
|
|
gptkbp:bfsParent
|
gptkb:Soliqua
gptkb:GLP-1_(Glucagon-like_peptide-1)
gptkb:GLP-1
gptkb:GLP-1_agonists
|
|
gptkbp:bfsLayer
|
7
|